HIGH QUALITY SCIENTIFIC CONTENT,  ONLINE OPEN ACCESS,  GLOBAL SCIENTIFIC AUDIENCE,  COST EFFECTIVE, ANY ONE CAN DOWNLOAD REPRINTS 
Spreading knowledge

Google Scholar

Google Scholar

Archives

Back 

THIAZOLIDINEDIONES: AN OVERVIEW. Ramit Kapoor, Rashmi Arora, N.S.Gill

THIAZOLIDINEDIONES: AN OVERVIEW.

Ramit Kapoor, Rashmi Arora, N.S.Gill

International Journal of Natural Product Science 2012: Spl Issue 1:250.

Abstract(RBIP-250)

Thiazolidinediones (TZD) are oral antidiabetic compounds that decrease insulin resistance, used for the treatment of type 2 diabetes for almost a decade. These agents act through stimulation of the peroxisome proliferator-activated receptor (PPAR) a nuclear receptor present in various tissues. Apart from improving glycemic control, many background and clinical studies have shown that thiazolidinediones have beneficial effects on other components of metabolic syndrome and cardiovascular risk factors. Evidence suggests that these agents may have renal benefits. They were shown to reduce cardiovascular risk factors associated with this condition. There is also evidence that the use of TZDs in patients with impaired glucose tolerance (IGT) may preserve pancreatic beta-cell function, thereby delaying or preventing the onset of type 2 diabetes in this high-risk population. The heterodimer is formed which alter the gene transcription by binding to specific PPAR ( gamma 1 and 2) response elements in the promoter region of target genes , altering genes that control adipogenesis, lipid metabolism and glucose homeostasis. The PPAR-gamma1 isoform is expressed in many cell types, including adipocytes, osteoblasts, macrophages and muscle cells, while the PPAR-gamma2 isoform is restricted primarily to adipocytes.

Keywords: Antidiabetic, Thiazolidinediones, Cardiovascular, Glycemic, Osteoblast.
Attachments:
Time to create page: 0.16 seconds


Copyright © All rights reserved Science Instinct Publications sciipub.com